Back to top
more

Anika Therapeutics (ANIK)

(Delayed Data from NSDQ)

$25.58 USD

25.58
48,024

-0.32 (-1.24%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $25.59 +0.01 (0.04%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

New Strong Buy Stocks for December 14th

by Zacks Equity Research

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

by Zacks Equity Research

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why

by Zacks Equity Research

Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

by Zacks Equity Research

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

Novavax (NVAX) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

by Zacks Equity Research

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

by Zacks Equity Research

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Indrajit Bandyopadhyay headshot

Protect Your Portfolio From Volatility With 3 Low-Beta Picks

by Indrajit Bandyopadhyay

At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

by Zacks Equity Research

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

by Zacks Equity Research

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

by Zacks Equity Research

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

by Zacks Equity Research

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

by Zacks Equity Research

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

by Zacks Equity Research

Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.

Marinus (MRNS) Up 20% on Financial and Pipeline Updates

by Zacks Equity Research

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.